KR101923751B1 - 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체 - Google Patents

의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체 Download PDF

Info

Publication number
KR101923751B1
KR101923751B1 KR1020137022330A KR20137022330A KR101923751B1 KR 101923751 B1 KR101923751 B1 KR 101923751B1 KR 1020137022330 A KR1020137022330 A KR 1020137022330A KR 20137022330 A KR20137022330 A KR 20137022330A KR 101923751 B1 KR101923751 B1 KR 101923751B1
Authority
KR
South Korea
Prior art keywords
charom
arom
mmol
reaction
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137022330A
Other languages
English (en)
Korean (ko)
Other versions
KR20140014147A (ko
Inventor
엘 바쉬르 깔롱
까렝 브드제귀에랄
레미 라뽀
앙나 끄뤼끄진스키
필리프 쉬미뜨
미셀 쁘레
니꼴라 라이엘
Original Assignee
피에르 파브르 메디카먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피에르 파브르 메디카먼트 filed Critical 피에르 파브르 메디카먼트
Publication of KR20140014147A publication Critical patent/KR20140014147A/ko
Application granted granted Critical
Publication of KR101923751B1 publication Critical patent/KR101923751B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137022330A 2011-01-27 2012-01-27 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체 Expired - Fee Related KR101923751B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament
FR1150651 2011-01-27
PCT/EP2012/051283 WO2012101239A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187031264A Division KR20180122028A (ko) 2011-01-27 2012-01-27 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체

Publications (2)

Publication Number Publication Date
KR20140014147A KR20140014147A (ko) 2014-02-05
KR101923751B1 true KR101923751B1 (ko) 2018-11-29

Family

ID=44318089

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137022330A Expired - Fee Related KR101923751B1 (ko) 2011-01-27 2012-01-27 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체
KR1020187031264A Ceased KR20180122028A (ko) 2011-01-27 2012-01-27 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187031264A Ceased KR20180122028A (ko) 2011-01-27 2012-01-27 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체

Country Status (30)

Country Link
US (2) US20130172360A1 (cg-RX-API-DMAC10.html)
EP (1) EP2668184B1 (cg-RX-API-DMAC10.html)
JP (1) JP5931926B2 (cg-RX-API-DMAC10.html)
KR (2) KR101923751B1 (cg-RX-API-DMAC10.html)
CN (1) CN103339129B (cg-RX-API-DMAC10.html)
AR (1) AR084935A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012210467B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013018852B1 (cg-RX-API-DMAC10.html)
CA (1) CA2823824C (cg-RX-API-DMAC10.html)
CY (1) CY1120088T1 (cg-RX-API-DMAC10.html)
DK (1) DK2668184T3 (cg-RX-API-DMAC10.html)
ES (1) ES2661695T3 (cg-RX-API-DMAC10.html)
FR (1) FR2970967B1 (cg-RX-API-DMAC10.html)
HR (1) HRP20180524T1 (cg-RX-API-DMAC10.html)
HU (1) HUE037153T2 (cg-RX-API-DMAC10.html)
IL (2) IL227496B (cg-RX-API-DMAC10.html)
LT (1) LT2668184T (cg-RX-API-DMAC10.html)
MA (1) MA34903B1 (cg-RX-API-DMAC10.html)
MX (1) MX356411B (cg-RX-API-DMAC10.html)
MY (1) MY180666A (cg-RX-API-DMAC10.html)
PL (1) PL2668184T3 (cg-RX-API-DMAC10.html)
PT (1) PT2668184T (cg-RX-API-DMAC10.html)
RS (1) RS57101B1 (cg-RX-API-DMAC10.html)
RU (1) RU2600976C2 (cg-RX-API-DMAC10.html)
SI (1) SI2668184T1 (cg-RX-API-DMAC10.html)
TN (1) TN2013000293A1 (cg-RX-API-DMAC10.html)
TR (1) TR201802944T4 (cg-RX-API-DMAC10.html)
TW (1) TWI546303B (cg-RX-API-DMAC10.html)
UA (1) UA109698C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012101239A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150038295A (ko) * 2012-07-27 2015-04-08 피에르 파브르 메디카먼트 통증 치료용 아자인다졸 또는 디아자인다졸 타입의 유도체

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
US9458147B2 (en) 2012-02-22 2016-10-04 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AU2019264078A1 (en) * 2018-05-02 2020-12-17 Jw Pharmaceutical Corporation Novel heterocycle derivative
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
CN119241541A (zh) 2018-05-04 2025-01-03 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2023509421A (ja) * 2019-12-31 2023-03-08 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN115916771B (zh) * 2020-04-02 2025-04-01 浙江华海药业股份有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
WO2022106902A2 (en) 2020-11-20 2022-05-27 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041525A1 (en) 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
EP1292586B1 (en) 2000-06-22 2004-08-04 Pfizer Limited Process for the preparation of pyrazolopyrimidinones
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
BRPI0614884A2 (pt) * 2005-08-25 2011-04-19 Hoffmann La Roche inibidores de p38 map cinase e métodos para uso dos mesmos
AU2007275816A1 (en) 2006-07-17 2008-01-24 Merck Sharp & Dohme Corp. 1-hydroxy naphthyridine compounds as anti-HIV agents
CN101594862B (zh) 2006-12-20 2015-11-25 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代吲唑衍生物
CA2693901C (en) 2007-07-20 2015-12-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
ES2630026T3 (es) 2008-12-18 2017-08-17 Nerviano Medical Sciences S.R.L. Derivados indazólicos sustituidos activos como inhibidores de cinasa
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041525A1 (en) 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150038295A (ko) * 2012-07-27 2015-04-08 피에르 파브르 메디카먼트 통증 치료용 아자인다졸 또는 디아자인다졸 타입의 유도체
KR102120505B1 (ko) * 2012-07-27 2020-06-08 피에르 파브르 메디카먼트 통증 치료용 아자인다졸 또는 디아자인다졸 타입의 유도체

Also Published As

Publication number Publication date
MA34903B1 (fr) 2014-02-01
US20130085144A1 (en) 2013-04-04
FR2970967A1 (fr) 2012-08-03
UA109698C2 (xx) 2015-09-25
TWI546303B (zh) 2016-08-21
KR20180122028A (ko) 2018-11-09
CN103339129A (zh) 2013-10-02
SI2668184T1 (en) 2018-06-29
PL2668184T3 (pl) 2018-06-29
IL257748B (en) 2020-06-30
RS57101B1 (sr) 2018-06-29
IL257748A (en) 2018-04-30
RU2013138624A (ru) 2015-03-10
CA2823824A1 (en) 2012-08-02
EP2668184B1 (en) 2018-01-10
PT2668184T (pt) 2018-03-13
TR201802944T4 (tr) 2018-03-21
JP5931926B2 (ja) 2016-06-08
MX356411B (es) 2018-05-24
IL227496B (en) 2019-02-28
BR112013018852B1 (pt) 2021-12-21
MY180666A (en) 2020-12-04
MX2013008673A (es) 2013-12-02
US20130172360A1 (en) 2013-07-04
DK2668184T3 (en) 2018-03-12
RU2600976C2 (ru) 2016-10-27
HK1186737A1 (en) 2014-03-21
JP2014503574A (ja) 2014-02-13
CN103339129B (zh) 2015-07-29
WO2012101239A1 (en) 2012-08-02
NZ614432A (en) 2015-03-27
AR084935A1 (es) 2013-07-10
HUE037153T2 (hu) 2018-08-28
TN2013000293A1 (en) 2015-01-20
ES2661695T3 (es) 2018-04-03
BR112013018852A2 (pt) 2017-08-15
CA2823824C (en) 2018-12-11
HRP20180524T1 (hr) 2018-05-04
FR2970967B1 (fr) 2013-02-15
EP2668184A1 (en) 2013-12-04
US8883821B2 (en) 2014-11-11
AU2012210467B2 (en) 2016-07-07
AU2012210467A1 (en) 2013-09-12
IL227496A0 (en) 2013-09-30
TW201247664A (en) 2012-12-01
CY1120088T1 (el) 2018-12-12
LT2668184T (lt) 2018-04-10
KR20140014147A (ko) 2014-02-05

Similar Documents

Publication Publication Date Title
KR101923751B1 (ko) 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체
JP6732855B2 (ja) 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体
EP2877176B1 (en) Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
HK1186737B (en) Derivatives of azaindazole or diazaindazole type as medicament
OA16493A (en) Derivatives of azaindazole or diazaindazole type as medicament.
NZ614432B2 (en) Derivatives of azaindazole or diazaindazole type as medicament
HK1207302B (en) Derivatives of azaindazole or diazaindazole type for treating pain

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241124

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241124

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241124